NICE gives Glivec final nod for GIST
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has recommended Novartis's Glivec (imatinib) in final guidance for patients who have had gastro-intestinal stromal tumors (GIST) removed and are at high risk of the cancer returning.